Pro Medicus And 2 Other High Growth Tech Stocks In Australia
In the current Australian market landscape, the ASX 200 futures are indicating a slight dip of -0.2% amid geopolitical tensions and mixed economic signals, while unemployment remains stable at 4.1%. Against this backdrop, high growth tech stocks like Pro Medicus are garnering attention for their potential to thrive in uncertain conditions by leveraging innovation and adaptability to navigate market challenges.
Name
Revenue Growth
Earnings Growth
Growth Rating
Gratifii
42.14%
113.99%
★★★★★★
Pro Medicus
22.19%
23.49%
★★★★★★
WiseTech Global
20.15%
25.52%
★★★★★★
Wrkr
56.40%
116.83%
★★★★★★
AVA Risk Group
29.15%
108.15%
★★★★★★
Echo IQ
61.50%
65.86%
★★★★★★
BlinkLab
65.54%
64.35%
★★★★★★
Immutep
70.42%
42.39%
★★★★★☆
Adveritas
52.34%
88.83%
★★★★★★
SiteMinder
19.89%
69.58%
★★★★★☆
Click here to see the full list of 47 stocks from our ASX High Growth Tech and AI Stocks screener.
Let's dive into some prime choices out of from the screener.
Simply Wall St Growth Rating: ★★★★★★
Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$28.92 billion.
Operations: Pro Medicus Limited generates revenue primarily through the production of integrated software applications for the healthcare industry, totaling A$184.58 million. The company's operations span Australia, North America, and Europe, focusing on imaging software and radiology information systems for medical facilities.
Pro Medicus, a standout in the Australian tech landscape, exemplifies robust growth with its revenue and earnings forecast to expand at 22.2% and 23.5% per annum respectively, significantly outpacing the broader market's expectations. This performance is bolstered by strategic share repurchases, with a recent buyback of 28,326 shares for AUD 6.35 million enhancing shareholder value. Additionally, inclusion in the S&P International 700 and Global 1200 indices not only underscores its market relevance but also augments its visibility among global investors. The company's commitment to innovation is evident from its R&D initiatives aimed at advancing healthcare technology solutions—a sector witnessing rapid growth due to increasing demand for efficient medical services.
Navigate through the intricacies of Pro Medicus with our comprehensive health report here.
Explore historical data to track Pro Medicus' performance over time in our Past section.
Simply Wall St Growth Rating: ★★★★☆☆
Overview: SEEK Limited operates as an online employment marketplace service provider across Australia, South East Asia, New Zealand, the United Kingdom, Europe, and other international markets with a market cap of A$8.55 billion.
Operations: The company generates revenue primarily through its employment marketplace services, with A$821.40 million from the ANZ region and A$240.90 million from Asia.
Amidst a challenging landscape, SEEK has demonstrated resilience with its revenue and earnings poised for significant growth. Despite a substantial one-off loss of A$119.8 million last year, the company's revenue is expected to rise by 9.1% annually, outpacing the Australian market's growth of 5.6%. Furthermore, SEEK's earnings are forecasted to surge by 25.9% per year, notably higher than the market average of 11.6%. This robust financial outlook is underpinned by strategic initiatives and an Analyst/Investor Day that highlighted future prospects, reinforcing SEEK's potential in a competitive sector.
Unlock comprehensive insights into our analysis of SEEK stock in this health report.
Understand SEEK's track record by examining our Past report.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Telix Pharmaceuticals Limited is a commercial-stage biopharmaceutical company that develops and commercializes therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases, with a market cap of A$8.43 billion.
Operations: Telix Pharmaceuticals generates revenue primarily from its Precision Medicine segment, which accounts for A$771.11 million, while its Therapeutics and Manufacturing Solutions segments contribute A$9.35 million and A$2.75 million, respectively.
Telix Pharmaceuticals has demonstrated a robust trajectory in the high-growth tech sector, particularly through its innovative approaches in prostate cancer imaging. With a staggering annual earnings growth of 858% last year and an expected annual revenue increase of 19.8%, Telix outpaces the Australian market's average growth significantly. Recent strategic product launches, like the AlFluor™ platform and Illuccix®, have not only expanded its portfolio but also fortified its market position by enhancing diagnostic precision and treatment efficacy in oncology. These developments underscore Telix's commitment to advancing healthcare technology, positioning it well for sustained growth amidst evolving medical demands.
Delve into the full analysis health report here for a deeper understanding of Telix Pharmaceuticals.
Gain insights into Telix Pharmaceuticals' past trends and performance with our Past report.
Click here to access our complete index of 47 ASX High Growth Tech and AI Stocks.
Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments.
Enhance your investing ability with the Simply Wall St app and enjoy free access to essential market intelligence spanning every continent.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:PME ASX:SEK and ASX:TLX.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Shares dip in Asia, oil up as world awaits Iran response
By Wayne Cole SYDNEY (Reuters) -Wall Street share futures slipped on Monday and oil prices briefly hit five-month highs as investors anxiously waited to see if Iran would retaliate to U.S. attacks on its nuclear sites, with resulting risks to global activity and inflation. Early moves were contained, with the dollar getting only a minor safe-haven bid and no sign of panic selling across markets. Oil prices were up around 2%, but already well off their initial peaks. Optimists were hoping Iran might back down now its nuclear ambitions had been curtailed, or even that regime change might bring a less hostile government to power there. Analysts at JPMorgan, however, cautioned that past episodes of regime change in the region typically resulted in oil prices spiking by as much as 76% and averaging a 30% rise over time. Key will be access through the Strait of Hormuz, which is only about 33 km (21 miles) wide at its narrowest point and sees around 20% of the world's daily oil consumption. "With the U.S. becoming involved, the risk of Iran retaliating by disrupting the flows of oil from the Middle East has risen significantly," warned analysts at ANZ. "Prices in the $90–95/bbl range would be the likely outcome." For now, Brent was up a relatively restrained 1.9% at $78.46 a barrel, while U.S. crude rose 2% to $75.30. Elsewhere in commodity markets, gold edged up 0.2% to $3,375 an ounce. [GOL/] Share markets were proving resilient so far, with S&P 500 futures off 0.3% and Nasdaq futures down 0.5%, having both started with losses near 1%. Nikkei futures were just a fraction lower at 38,380, pointing to a small opening fall for the cash index. The dollar edged up 0.2% on the Japanese yen to 146.36 yen, while the euro dipped 0.3% to $1.1485. The dollar index firmed 0.25% to 99.008. There was also no sign of a rush to the traditional safety of Treasuries, with futures up only 1 tick. Futures for Federal Reserve interest rates were a tick lower, likely reflecting concerns a sustained rise in oil prices would add to inflationary pressures at a time when tariffs were just being felt in U.S. prices. Markets are still pricing a slim chance the Fed will cut at its next meeting on July 30, even after Fed Governor Christopher Waller broke ranks and argued for a July easing. Most other Fed members, including Chair Jerome Powell, have been more cautious on policy leading markets to wager a cut is far more likely in September. At least 15 Fed officials are speaking this week, and Powell faces two days of questions from lawmakers, which is certain to cover the potential impact of President Donald Trump's tariffs and the attack on Iran. The Middle East will be high on the agenda at a NATO leaders meeting at the Hague this week, where most members have agreed to commit to a sharp rise in defence spending. Among the economic data due are figures on U.S. core inflation and weekly jobless claims, along with early readings on June factory activity from across the globe. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
34 minutes ago
- Yahoo
Kinder Morgan Maintains Strong Dividend Appeal with Growing Project Backlog
Kinder Morgan, Inc. (NYSE:KMI) is one of the 10 best dividend stocks according to Jim Cramer. UBS has reiterated a Buy rating on the company's stock, with a price target of $38. Aerial view of an oil and gas pipeline, spanning vast landscapes. One of the largest energy infrastructures in North America, Kinder Morgan, Inc. (NYSE:KMI) owns and operates 83,000 miles of pipelines and 141 terminals. Based in Texas, the company transports a range of products, including natural gas, gasoline, crude oil, and CO2. Using its terminals, the company also stores and handles commodities like petroleum products, chemicals, and renewable fuels. In April, Kinder Morgan, Inc. (NYSE:KMI) reported its Q1 2025 results, whereby it stated adding approximately $900 million to its project backlog. 70% of it is focused on serving power demand. Particularly, the company noted a record high demand for natural gas during the quarter, improving its outlook. Following the company's progress, UBS reiterated a Buy rating on the stock on June 11, 2025. It maintained the rating further on June 16, 2025, with a price target of $38, indicating a strong confidence in the company's performance ahead. Kinder Morgan, Inc. (NYSE:KMI) offers a dividend yield of 4.23%, attracting income-seeking investors. However, the 99.14% payout ratio indicates that the company may not be retaining any earnings for investment. Paying dividends quarterly, the company has held 8 years of consecutive growth. While we acknowledge the potential of KMI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: andDisclosure. None. Connectez-vous pour accéder à votre portefeuille
Yahoo
38 minutes ago
- Yahoo
Institutions own 29% of Macmahon Holdings Limited (ASX:MAH) shares but public companies control 45% of the company
Significant control over Macmahon Holdings by public companies implies that the general public has more power to influence management and governance-related decisions A total of 2 investors have a majority stake in the company with 53% ownership 29% of Macmahon Holdings is held by Institutions This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. A look at the shareholders of Macmahon Holdings Limited (ASX:MAH) can tell us which group is most powerful. We can see that public companies own the lion's share in the company with 45% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company. Meanwhile, institutions make up 29% of the company's shareholders. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. In the chart below, we zoom in on the different ownership groups of Macmahon Holdings. See our latest analysis for Macmahon Holdings Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. As you can see, institutional investors have a fair amount of stake in Macmahon Holdings. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Macmahon Holdings, (below). Of course, keep in mind that there are other factors to consider, too. Macmahon Holdings is not owned by hedge funds. The company's largest shareholder is PT Amman Mineral Internasional Tbk, with ownership of 45%. Meanwhile, the second and third largest shareholders, hold 7.7% and 3.8%, of the shares outstanding, respectively. To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves. I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions. Our most recent data indicates that insiders own some shares in Macmahon Holdings Limited. As individuals, the insiders collectively own AU$14m worth of the AU$655m company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling. The general public, who are usually individual investors, hold a 21% stake in Macmahon Holdings. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run. We can see that public companies hold 45% of the Macmahon Holdings shares on issue. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching this space for changes in ownership. While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should be aware of the 1 warning sign we've spotted with Macmahon Holdings . But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. — Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
